Literature DB >> 17077327

FGF2 posttranscriptionally down-regulates expression of SDF1 in bone marrow stromal cells through FGFR1 IIIc.

Takayuki Nakayama1, Noriko Mutsuga, Giovanna Tosato.   

Abstract

The chemokine stromal cell-derived factor-1 (SDF-1) is constitutively expressed by bone marrow stromal cells and plays key roles in hematopoiesis. Fibroblast growth factor 2 (FGF2), a member of the FGF family that plays important roles in developmental morphogenic processes, is abnormally elevated in the bone marrow from patients with clonal myeloid disorders and other disorders where normal hematopoiesis is impaired. Here, we report that FGF2 reduces SDF-1 secretion and protein content in bone marrow stromal cells. By inhibiting SDF-1 production, FGF2 compromises stromal cell support of hematopoietic progenitor cells. Reverse-transcriptase-polymerase chain reaction (RT-PCR) analysis revealed that bone marrow stromal cells express 5 FGF receptors (FGFRs) among the 7 known FGFR subtypes. Blocking experiments identified FGFR1 IIIc as the receptor mediating FGF2 inhibition of SDF-1 expression in bone marrow stromal cells. Analysis of the mechanisms underlying FGF2 inhibition of SDF-1 production in bone marrow stromal cells revealed that FGF2 reduces the SDF-1 mRNA content by posttranscriptionally accelerating SDF-1 mRNA decay. Thus, we identify FGF2 as an inhibitor of SDF-1 production in bone marrow stromal cells and a regulator of stromal cell supportive functions for hematopoietic progenitor cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17077327      PMCID: PMC1794071          DOI: 10.1182/blood-2006-06-028217

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  83 in total

1.  G-CSF is an essential regulator of neutrophil trafficking from the bone marrow to the blood.

Authors:  Craig L Semerad; Fulu Liu; Alyssa D Gregory; Katherine Stumpf; Daniel C Link
Journal:  Immunity       Date:  2002-10       Impact factor: 31.745

2.  Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family.

Authors:  A M Lambeir; P Proost; C Durinx; G Bal; K Senten; K Augustyns; S Scharpé; J Van Damme; I De Meester
Journal:  J Biol Chem       Date:  2001-06-04       Impact factor: 5.157

3.  Leukocyte elastase negatively regulates Stromal cell-derived factor-1 (SDF-1)/CXCR4 binding and functions by amino-terminal processing of SDF-1 and CXCR4.

Authors:  Agustín Valenzuela-Fernández; Thierry Planchenault; Françoise Baleux; Isabelle Staropoli; Karine Le-Barillec; Dominique Leduc; Thierry Delaunay; Françoise Lazarini; Jean-Louis Virelizier; Michel Chignard; Dominique Pidard; Fernando Arenzana-Seisdedos
Journal:  J Biol Chem       Date:  2002-02-26       Impact factor: 5.157

4.  Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1.

Authors:  Ombretta Salvucci; Lei Yao; Sabrina Villalba; Agatha Sajewicz; Stefania Pittaluga; Giovanna Tosato
Journal:  Blood       Date:  2002-04-15       Impact factor: 22.113

5.  Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide.

Authors:  Jean-Pierre Lévesque; Jean Hendy; Yasushi Takamatsu; Paul J Simmons; Linda J Bendall
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

6.  Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist.

Authors:  W Conrad Liles; Hal E Broxmeyer; Elin Rodger; Brent Wood; Kai Hübel; Scott Cooper; Giao Hangoc; Gary J Bridger; Geoffrey W Henson; Gary Calandra; David C Dale
Journal:  Blood       Date:  2003-07-10       Impact factor: 22.113

7.  Transforming growth factor-beta1 down-regulates expression of chemokine stromal cell-derived factor-1: functional consequences in cell migration and adhesion.

Authors:  Natalia Wright; Teresa Laín de Lera; Carelia García-Moruja; Rosa Lillo; Félix García-Sánchez; Antonio Caruz; Joaquin Teixidó
Journal:  Blood       Date:  2003-05-29       Impact factor: 22.113

8.  Transgenic expression of stromal cell-derived factor-1/CXC chemokine ligand 12 enhances myeloid progenitor cell survival/antiapoptosis in vitro in response to growth factor withdrawal and enhances myelopoiesis in vivo.

Authors:  Hal E Broxmeyer; Scott Cooper; Lisa Kohli; Giao Hangoc; Younghee Lee; Charlie Mantel; D Wade Clapp; Chang H Kim
Journal:  J Immunol       Date:  2003-01-01       Impact factor: 5.422

9.  Proline to arginine mutations in FGF receptors 1 and 3 result in Pfeiffer and Muenke craniosynostosis syndromes through enhancement of FGF binding affinity.

Authors:  Omar A Ibrahimi; Fuming Zhang; Anna V Eliseenkova; Robert J Linhardt; Moosa Mohammadi
Journal:  Hum Mol Genet       Date:  2003-11-12       Impact factor: 6.150

10.  G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4.

Authors:  Isabelle Petit; Martine Szyper-Kravitz; Arnon Nagler; Meir Lahav; Amnon Peled; Liliana Habler; Tanya Ponomaryov; Russell S Taichman; Fernando Arenzana-Seisdedos; Nobutaka Fujii; Judith Sandbank; Dov Zipori; Tsvee Lapidot
Journal:  Nat Immunol       Date:  2002-06-17       Impact factor: 25.606

View more
  13 in total

1.  Fibroblast growth factor receptors control epithelial-mesenchymal interactions necessary for alveolar elastogenesis.

Authors:  Sorachai Srisuma; Soumyaroop Bhattacharya; Dawn M Simon; Siva K Solleti; Shivraj Tyagi; Barry Starcher; Thomas J Mariani
Journal:  Am J Respir Crit Care Med       Date:  2010-01-21       Impact factor: 21.405

Review 2.  Multiple signaling interactions coordinate collective cell migration of the posterior lateral line primordium.

Authors:  Andy Aman; Tatjana Piotrowski
Journal:  Cell Adh Migr       Date:  2009-10-20       Impact factor: 3.405

3.  Membrane estrogen signaling enhances tumorigenesis and metastatic potential of breast cancer cells via estrogen receptor-α36 (ERα36).

Authors:  Reyhaan A Chaudhri; Rene Olivares-Navarrete; Natalia Cuenca; Agreen Hadadi; Barbara D Boyan; Zvi Schwartz
Journal:  J Biol Chem       Date:  2012-01-13       Impact factor: 5.157

4.  Differential regulation of CXCL5 by FGF2 in osteoblastic and endothelial niche cells supports hematopoietic stem cell migration.

Authors:  Kyung-Ae Yoon; Hye-Sim Cho; Hong-In Shin; Je-Yoel Cho
Journal:  Stem Cells Dev       Date:  2012-09-04       Impact factor: 3.272

5.  Stromal cell-derived factor-1 promotes bone marrow-derived cells differentiation to cardiomyocyte phenotypes in vitro.

Authors:  M Chen; H-Q Xie; L Deng; X-Q Li; Y Wang; W Zhi; Z-M Yang
Journal:  Cell Prolif       Date:  2008-04       Impact factor: 6.831

6.  MiR-886-3p down regulates CXCL12 (SDF1) expression in human marrow stromal cells.

Authors:  Manoj M Pillai; Xiaodong Yang; Ilango Balakrishnan; Lynne Bemis; Beverly Torok-Storb
Journal:  PLoS One       Date:  2010-12-13       Impact factor: 3.240

7.  Erythroid promoter confines FGF2 expression to the marrow after hematopoietic stem cell gene therapy and leads to enhanced endosteal bone formation.

Authors:  Xianmei Meng; David J Baylink; Matilda Sheng; Hongjie Wang; Daila S Gridley; K-H William Lau; Xiao-Bing Zhang
Journal:  PLoS One       Date:  2012-05-18       Impact factor: 3.240

8.  COUP-TFI modifies CXCL12 and CXCR4 expression by activating EGF signaling and stimulates breast cancer cell migration.

Authors:  Antoine Boudot; Gwenneg Kerdivel; Sylvain Lecomte; Gilles Flouriot; Mireille Desille; Florence Godey; Jean Leveque; Patrick Tas; Yves Le Dréan; Farzad Pakdel
Journal:  BMC Cancer       Date:  2014-06-06       Impact factor: 4.430

9.  Fgf and Sdf-1 pathways interact during zebrafish fin regeneration.

Authors:  Mohamed Bouzaffour; Pascale Dufourcq; Virginie Lecaudey; Petra Haas; Sophie Vriz
Journal:  PLoS One       Date:  2009-06-08       Impact factor: 3.240

10.  Secretion of SDF-1alpha by bone marrow-derived stromal cells enhances skin wound healing of C57BL/6 mice exposed to ionizing radiation.

Authors:  Yannick Landry; Oanh Lê; Kimberly A Mace; Terry E Restivo; Christian M Beauséjour
Journal:  J Cell Mol Med       Date:  2009-09-01       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.